Meeting Report
Thoracic Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC
J Adv Pract Oncol 2022;13(6):579-585 |
https://doi.org/10.6004/jadpro.2022.13.6.3 |
© 2022 Harborside™
ABSTRACT
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews research in thoracic cancers presented at the 2022 ASCO Annual Meeting, including neoadjuvant immunotherapy for resectable stage IIIA non–small cell lung cancer, a new drug inhibiting KRAS G12C, and options after disease progression on immune checkpoint inhibitor treatment or targeted treatment.
For access to the full length article, please
sign in.
